News
Oxford University vaccine trial paused after participant falls ill
Final clinical trials for a coronavirus vaccine, developed by AstraZeneca and Oxford University, have been put on hold after a participant had a suspected adverse reaction in the UK.
AstraZeneca described it as a "routine" pause in the case of...
IT & Data Management
Chugai and NTT DATA Complete Demonstration of AI-based Clinical Trial Efficiency Solution
Chugai Pharmaceutical Co., Ltd. and NTT DATA Corporation have conducted a demonstration test of a solution for improving the efficiency of clinical trial-related document preparation using AI technology from January to June, 2020.
Clinical trial operations require the creation of...
News
Avacta to Launch SARS-CoV-2 ELISA Laboratory Test
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Enzyme linked...
News
Vibalogics appoints global CEO to lead U.S. expansion
Vibalogics, a global contract development and manufacturing organization (CDMO) that specializes in the production of virotherapy products, has announced the appointment of Tom Hochuli as Chief Executive Officer as the company accelerates its U.S. expansion and global growth strategy.
Bringing...
News
Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine
Intravacc, a global provider of translational research and development of viral and bacterial vaccines, has been awarded a contract with base and options that may total $9.4 million from the U.S. National Institute of Allergy and Infectious Diseases (NIAID),...
News
Cipla Health ventures into antifungal product category with launch of Clocip
Cipla Health Ltd., a leading consumer healthcare brand, has forayed into the antifungal product category with the introduction of Clocip, to offer a hardworking skin infection solution for hardworking people enabling them to continue work without any discomfort.
Available in...
News
Roche announces FDA approval of Gavreto for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
Roche announced that the United States (US) FDA has approved Gavreto™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
